Focus: Vantive is a biotechnology company headquartered in Deerfield, IL, focused on vital organ therapy products and digital solutions primarily in nephrology. The company markets dialysis solutions and related renal care products for acute and chronic kidney disease management.
Profile data last refreshed 21h ago · AI intelligence enriched 2d ago
No open roles listed right now. Follow Vantive to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Vantive's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship peritoneal dialysis solution for end-stage renal disease; approaching loss of exclusivity poses revenue risk.
Help build intelligence for Vantive
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Critical renal replacement therapy solution for intensive care settings; approaching exclusivity loss.
Renal replacement solution for electrolyte and acid-base management; approaching loss of exclusivity.
Peak-lifecycle renal replacement therapy solution; currently the strongest product in portfolio by lifecycle stage.
Peritoneal dialysis formulation for renal failure management; approaching exclusivity loss.
Renal replacement solution variant; approaching loss of exclusivity.
Specialized renal replacement formulation; approaching loss of exclusivity.
Peritoneal dialysis solution for renal failure management; approaching exclusivity loss.
Peritoneal dialysis formulation for end-stage renal disease; approaching loss of exclusivity.
Peritoneal dialysis solution for renal failure; approaching loss of exclusivity threatens revenue.
17 discontinued, 19 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo